Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
University of Maryland Saint Joseph Medical Center
mi
from
Towson, MD
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
University of Maryland Saint Joseph Medical Center
mi
from
Towson, MD
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
University of Michigan
mi
from
Ann Arbor, MI
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Saint John's Mercy Medical Center
mi
from
Saint Louis, MO
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Saint John's Mercy Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Montefiore Medical Center-Weiler Division
mi
from
Bronx, NY
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Montefiore Medical Center-Weiler Division
mi
from
Bronx, NY
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
New York University Clinical Cancer Center
mi
from
New York, NY
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
New York University Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
Weill Medical College of Cornell University
mi
from
New York, NY
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated:  7/20/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)
Status: Enrolling
Updated: 7/20/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  7/20/2015
Clinical Research Facility
mi
from
Loma Linda, CA
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 7/20/2015
Clinical Research Facility
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  7/20/2015
Clinical Research Facility
mi
from
Washington,
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 7/20/2015
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  7/20/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 7/20/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  7/20/2015
Clinical Research Facility
mi
from
Tampa, FL
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 7/20/2015
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  7/20/2015
Clinical Research Facility
mi
from
Decatur, IL
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 7/20/2015
Clinical Research Facility
mi
from
Decatur, IL
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  7/20/2015
Clinical Research Facility
mi
from
Metairie, LA
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 7/20/2015
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  7/20/2015
Clinical Research Facility
mi
from
Baltimore, MD
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 7/20/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  7/20/2015
Clinical Research Facility
mi
from
Boston, MA
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 7/20/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  7/20/2015
Clinical Research Facility
mi
from
St Louis, MO
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 7/20/2015
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  7/20/2015
Clinical Research Facility
mi
from
Canton, OH
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 7/20/2015
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  7/20/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 7/20/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  7/20/2015
Clinical Research Facility
mi
from
Bethlehem, PA
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 7/20/2015
Clinical Research Facility
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  7/20/2015
Clinical Research Facility
mi
from
San Antonio, TX
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 7/20/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  7/20/2015
Clinical Research Facility
mi
from
La Jolla, CA
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 7/20/2015
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Improving Management of Breathlessness in Patients With Lung Cancer
Improving Management of Breathlessness in Patients With Lung Cancer
Status: Enrolling
Updated:  7/20/2015
Massachusetts General Hospital
mi
from
Boston, MA
Improving Management of Breathlessness in Patients With Lung Cancer
Improving Management of Breathlessness in Patients With Lung Cancer
Status: Enrolling
Updated: 7/20/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Med Diet Prevention Metabolic Syndrome Men Undergoing Androgen Deprivation Therapy Prostate Cancer
Eight Week Plant-based Mediterranean Diet as Prevention of Metabolic Syndrome in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer: A BrUOG Pilot Study
Status: Enrolling
Updated:  7/21/2015
Miriam Hospital
mi
from
Providence, RI
Med Diet Prevention Metabolic Syndrome Men Undergoing Androgen Deprivation Therapy Prostate Cancer
Eight Week Plant-based Mediterranean Diet as Prevention of Metabolic Syndrome in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer: A BrUOG Pilot Study
Status: Enrolling
Updated: 7/21/2015
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer
Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer
Status: Enrolling
Updated:  7/21/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer
Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer
Status: Enrolling
Updated: 7/21/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Chemotherapy Monitoring With Breast Computed Tomography (CT)
Breast Cancer Chemotherapy Monitoring With Dedicated Breast Computed Tomography
Status: Enrolling
Updated:  7/21/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Chemotherapy Monitoring With Breast Computed Tomography (CT)
Breast Cancer Chemotherapy Monitoring With Dedicated Breast Computed Tomography
Status: Enrolling
Updated: 7/21/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Breast Computed Tomography (CT) as a Diagnostic Tool
Breast CT as a Diagnostic Tool
Status: Enrolling
Updated:  7/21/2015
Emory University Hospital Breast Imaging Center
mi
from
Atlanta, GA
Breast Computed Tomography (CT) as a Diagnostic Tool
Breast CT as a Diagnostic Tool
Status: Enrolling
Updated: 7/21/2015
Emory University Hospital Breast Imaging Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Breast and Cervical Cancer Educational Intervention for Latinas in Western New York
Investigating a Breast and Cervical Cancer Intervention for Latinas in Western New York
Status: Enrolling
Updated:  7/21/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Breast and Cervical Cancer Educational Intervention for Latinas in Western New York
Investigating a Breast and Cervical Cancer Intervention for Latinas in Western New York
Status: Enrolling
Updated: 7/21/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Hypofractionated Radiotherapy for Lung Cancer
The Use of Helical Tomotherapy to Achieve Dose-per-fraction Escalation in Lung Cancer
Status: Enrolling
Updated:  7/22/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Hypofractionated Radiotherapy for Lung Cancer
The Use of Helical Tomotherapy to Achieve Dose-per-fraction Escalation in Lung Cancer
Status: Enrolling
Updated: 7/22/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Estrogen for Triple Negative Breast Cancer
A Phase II Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer
Status: Enrolling
Updated:  7/22/2015
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Estrogen for Triple Negative Breast Cancer
A Phase II Study of High Dose Estradiol in Metastatic Triple Negative Breast Cancer
Status: Enrolling
Updated: 7/22/2015
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/22/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/22/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/22/2015
Southern Illinois University School of Medicine - Obstetrics and Oncology
mi
from
Springfield, IL
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/22/2015
Southern Illinois University School of Medicine - Obstetrics and Oncology
mi
from
Springfield, IL
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/22/2015
Saint John's Mercy Medical Center
mi
from
Saint Louis, MO
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/22/2015
Saint John's Mercy Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/22/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/22/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/22/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/22/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/22/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/22/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/22/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/22/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/22/2015
City of Hope Medical Center
mi
from
Duarte, CA
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/22/2015
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/22/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/22/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/22/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/22/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/22/2015
Moffitt Cancer Center
mi
from
Tampa, FL
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/22/2015
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/22/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/22/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/22/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/22/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/22/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/22/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  7/22/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
Phase II Randomized Study of Vorinostat or Placebo in Combination With Carboplatin and Paclitaxel for Patients With Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 7/22/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder
Status: Enrolling
Updated:  7/22/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder
Status: Enrolling
Updated: 7/22/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder
Status: Enrolling
Updated:  7/22/2015
Louis A. Weiss Memorial Hospital
mi
from
Chicago, IL
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder
Status: Enrolling
Updated: 7/22/2015
Louis A. Weiss Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder
Status: Enrolling
Updated:  7/22/2015
Vancouver General Hospital
mi
from
Vancouver,
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder
Status: Enrolling
Updated: 7/22/2015
Vancouver General Hospital
mi
from
Vancouver,
Click here to add this to my saved trials
Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
A Phase I Study Of Medi 522 In Patients With Advanced Tumors
Status: Enrolling
Updated:  7/22/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
A Phase I Study Of Medi 522 In Patients With Advanced Tumors
Status: Enrolling
Updated: 7/22/2015
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials